Taejoon Pharm Co Ltd-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Taejoon Pharm Co Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013258
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:16
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:韓国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Taejoon Pharm Co Ltd (Taejoon) is a pharmaceutical company that markets ophthalmic agents and other drugs. The company offers injections, powders, eye drops, spray, syrups, tablets, soft capsules, liquids for external use, and hard capsules. Its powder products comprise coolprep powder, taejoon top powder, solotop powder, colyte f powder, and colyte powder products. Taejoon also provides x-ray, MRI and CT media products. The company’s products are used in ophthalmological, laxative, gastrointestinal, and contrast media applications. It sells its products through a network of distributors in South Korea, Thailand, China, Russia, the UK and the US. Taejoon is headquartered in Seoul, South Korea.

Taejoon Pharm Co Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Taejoon Pharm Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Taejoon Pharm Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Taejoon Pharm Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Taejoon Pharm Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Taejoon Pharm Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Taejoon Pharm Co Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Taejoon Pharm Enters Into Co-Promotion Agreement With Handok Pharma For Gatiflo 10
Licensing Agreements 11
ORA Enters into Sublicense Agreement with Taejoon Pharm 11
Nippon Shinyaku Enters into Licensing Agreement with Taejoon Pharm for Gaslon N 12
Taejoon Pharm Co Ltd – Key Competitors 13
Taejoon Pharm Co Ltd – Key Employees 14
Taejoon Pharm Co Ltd – Locations And Subsidiaries 15
Head Office 15
Other Locations & Subsidiaries 15
Appendix 16
Methodology 16
About GlobalData 16
Contact Us 16
Disclaimer 16

List of Tables
Taejoon Pharm Co Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Taejoon Pharm Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Taejoon Pharm Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Taejoon Pharm Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Taejoon Pharm Co Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Taejoon Pharm Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Taejoon Pharm Enters Into Co-Promotion Agreement With Handok Pharma For Gatiflo 10
ORA Enters into Sublicense Agreement with Taejoon Pharm 11
Nippon Shinyaku Enters into Licensing Agreement with Taejoon Pharm for Gaslon N 12
Taejoon Pharm Co Ltd, Key Competitors 13
Taejoon Pharm Co Ltd, Key Employees 14
Taejoon Pharm Co Ltd, Other Locations 15

★海外企業調査レポート[Taejoon Pharm Co Ltd-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Regenicin Inc (RGIN):医療機器:M&Aディール及び事業提携情報
    Summary Regenicin Inc (Regenicin), formerly Windstar Inc is a biotechnology company that develops regenerative cell therapies. The company offers NovaDerm, a tissue-engineered skin prepared from autologous skin cells. Its NovaDerm technology uses the patient’s own skin cells to generate living, tiss …
  • TTM Technologies Inc:企業の戦略・SWOT・財務分析
    TTM Technologies Inc - Strategy, SWOT and Corporate Finance Report Summary TTM Technologies Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Japan Post Holdings Co., Ltd.:企業の戦略・SWOT・財務分析
    Japan Post Holdings Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Japan Post Holdings Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • AviAlliance GmbH:企業の戦略・SWOT・財務情報
    AviAlliance GmbH - Strategy, SWOT and Corporate Finance Report Summary AviAlliance GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Aero Components Inc.:企業の戦略・SWOT・財務情報
    Aero Components Inc. - Strategy, SWOT and Corporate Finance Report Summary Aero Components Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Shaw Communications Inc (SJR.B):企業の財務・戦略的SWOT分析
    Shaw Communications Inc (SJR.B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Quantum Pharma Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Quantum Pharma Ltd (Quantum Pharma), a subsidiary Clinigen Group Plc, is a manufacturer and supplier of unlicensed medicines. The company develops, manufactures, and supplies niche pharmaceutical products. It offers dermatology products, branded generics and vitamins, borderline substances, …
  • Oversea-Chinese Banking Corporation Ltd:企業のM&A・事業提携・投資動向
    Oversea-Chinese Banking Corporation Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Oversea-Chinese Banking Corporation Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed re …
  • Consolidated Edison Inc (ED):企業の財務・戦略的SWOT分析
    Consolidated Edison Inc (ED) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Fresenius Medical Care AG & Co KGaA (FMS):医療機器:M&Aディール及び事業提携情報
    Summary Fresenius Medical Care AG & Co KGaA (Fresenius Medical), a subsidiary of Fresenius SE & Co KGaA, is an integrated dialysis company. It is one of the largest kidney dialysis companies in the world. It provides dialysis care services and products to individuals with chronic kidney failure. It …
  • NovioSense BV-医療機器分野:企業M&A・提携分析
    Summary NovioSense BV (NovioSense) is a medical device company that develops a wireless technology platform for non-invasive monitoring of disease biomarkers. The company provides NovioSense, a glucose sensor to continuously monitor glucose levels in the tear fluid and sends a wireless signal to a h …
  • Epigenomics AG (ECX):製薬・医療:M&Aディール及び事業提携情報
    Summary Epigenomics AG (Epigenomics) is a molecular diagnostics company which develops and commercializes in-vitro diagnostic (IVD) tests for screening, early detection and diagnosis of cancer. Its lead product, Epi proColon is a blood-based test for rapid detection of colorectal cancer; and Epi pro …
  • Phibro Animal Health Corp (PAHC):企業の財務・戦略的SWOT分析
    Phibro Animal Health Corp (PAHC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Ford Motor Company:戦略・SWOT・企業財務分析
    Ford Motor Company - Strategy, SWOT and Corporate Finance Report Summary Ford Motor Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Helix Resources Ltd (HLX):企業の財務・戦略的SWOT分析
    Summary Helix Resources Ltd (HRL) operates as a mining and mineral exploration company. The company carries out the business of identification, acquisition, and development of mineral properties. It explores gold, copper, zinc, uranium, nickel, and iron ore properties. HRL's projects include Colleri …
  • Staatsolie Maatschappij Suriname NV:企業の戦略的SWOT分析
    Staatsolie Maatschappij Suriname NV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Ethypharm SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Ethypharm SA (Ethypharm), a subsidiary of Astorg Partners is a pharmaceutical company that develops and manufactures drugs for the treatment of pain, gastrointestinal, cancer, cardiovascular and central nervous system diseases. The company provides products such as ibuprofen, paracetamol, pr …
  • Ube Industries Ltd (4208):企業の財務・戦略的SWOT分析
    Ube Industries Ltd (4208) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • TransAlta Corp (TA):電力:M&Aディール及び事業提携情報
    Summary TransAlta Corp (TransAlta) is an electricity generation company. It owns, operates and develops a divergent fleet of electricity generation assets. It generates electricity from a contracted portfolio of assets using diverse sources such as coal, natural gas, hydro, wind and geothermal. Tran …
  • Galera Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Galera Therapeutics Inc (Galera Therapeutics) is a clinical-stage biotechnology company that discovers and develops novel cancer treatments. The company also concentrates on the prevention of radiation-induced toxicity including mucositis and the treatment of cancer. Its GC4419 is a selectiv …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆